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Drugs that are clinically effective against generalized anxiety disorder preferentially alter rodent risk assessment behavior, whereas drugs
that are clinically effective against panic disorder preferentially alter rodent flight behavior. The theoretical principle of “defensive
direction” explains the pattern of associations between emotion and defensive behavior in terms of the differing functional demands
arising from cautious approach to threat (anxiety) versus departure from threat (fear), offering the prospect that clinically important
emotions may be explained using a single rubric of defense. We used a within-subjects, placebo-controlled, design to test this theory,
measuring the effects of citalopram and lorazepam on the defensive behavior of 30 healthy adult male humans. We indexed human
defensive behavior with a translation of an active avoidance task used to measure rodent defense and found that lorazepam significantly
reduced the intensity of defensive behavior during approach to threat (hypothetically anxiety-related) but not departure from threat
(hypothetically fear-related). Contrary to prediction, citalopram did not affect either form of defensive reaction. Since lorazepam is a drug
with well established anxiety reducing properties, these data support the hypothesis that anxiety is an emotion elicited by threat stimuli
that require approach. These data also contribute to the validation of a novel human analog of an established experimental model of
rodent fear and anxiety.
Introduction
Rodent studies suggest that risk assessment and flight are key
components of the innate defensive repertoire of mammals
(Blanchard, 1997). Risk assessment behavior is typically elicited by
ambiguous threats such as suspicious noises or odors (Blanchard et
al., 2003) whereas flight behavior is typically elicited by clear
threat (e.g., a predator) in situations where an escape route is
available (Blanchard et al., 1989). Ethopharmacological analyses
of rodent defense (i.e., studies of drug effects on defensive behav-
ior in naturalistic but controlled settings) associate these two
behavior patterns with the emotions of anxiety and fear, respec-
tively (Blanchard and Blanchard, 2008), on the basis that anxio-
lytic drugs (which are successful in the treatment of human
anxiety) alter risk assessment (D. C. Blanchard et al., 1990),
whereas panicolytic drugs (which are successful in the treatment
of human fear/panic) alter flight (Griebel et al., 1995a).
The alteration of rodent defensive behavior by drugs that alter
human emotional states not only points to a defense-based ex-
planation for some affective disorders (Blanchard et al., 2001),
but also has allowed these rodent defense findings to be inte-
grated theoretically with the findings of earlier studies that exam-
ined the effects of such drugs on rodent behavior in classical
learning tasks. More specifically, the capacity of anxiolytic drugs
systematically to alter rodent behavior in goal conflict tasks that are
seemingly threat-free [e.g., delayed matching (Tan et al., 1990)] has
been cited as evidence that anxiety is a response to goal conflict
rather than ambiguous threat per se (Gray and McNaughton,
2000). According to this theory, a rodent’s need to investigate an
ambiguous threat to verify its dangerousness putatively generates
an approach-avoidance goal conflict that, in turn, elicits risk as-
sessment accompanied by anxiety (McNaughton and Corr,
2004). Emerging from this work is a theoretical principle known
as “defensive direction,” which postulates that anxiety is elicited
by threats requiring approach (i.e., that cause goal conflict) and
fear by threats that need not be approached, but simply avoided
(McNaughton and Corr, 2004; Corr, 2008).
We tested this theory by examining drug effects on human
behavior in a computerized translation of a rodent runway task
that has been used for ethopharmacological studies, namely the
mouse defense test battery (MDTB) (Griebel et al., 1997) (see Fig.
1A). The MDTB was selected as the basis for the present research
as it can be configured so that the mouse is trapped in a closed
runway or free to move along an endless runway. This dual con-
figuration design permits the systematic measurement of drug
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effects on behavior during approach to
threat (i.e., the putative eliciting stimulus
for anxiety/risk assessment) and depar-
ture from threat (i.e., the putative eliciting
stimulus for fear/flight), rendering it suit-
able for a pharmacological test of the prin-
ciple of defensive direction.
In our human translation of the MDTB
we measured the effects of citalopram,
lorazepam, and placebo on human behavior
in both MDTB configurations (Fig. 1B,C)
to test the idea that anxiety is elicited by
threats requiring approach and fear by
threats that need not be approached. We ac-
cordingly hypothesized that lorazepam, a
benzodiazepine drug with well established
anxiolytic properties (e.g., Gould et al.,
1997), would alter behavior during ap-
proach to threat but not departure from
threat. Conversely we hypothesized that
citalopram, a selective serotonin reuptake
inhibitor (SSRI) with well established pa-
nicolytic properties (Wade et al., 1997),
would alter behavior during departure
from threat but not approach to threat.
Materials and Methods
Participants
All participants gave written informed consent
before being enrolled. The study was approved
by the research ethics committee of King’s Col-
lege Hospital in London, UK. Thirty healthy
male participants (mean age  25.8, SD  6.0,
age range 18 – 40 years) completed the study via
a two-stage screening process: all initial re-
spondents to advertisements for the study were
screened by telephone using a detailed medical
checklist, with those that passed undergoing a
face-to-face semistructured clinical interview
with a consultant psychiatrist (lasting 40 – 60
min). This interview explored the participant’s
medical history in depth to determine their suitability for the study.
Exclusion criteria included psychiatric illness, serious head injury, dys-
lexia, learning difficulties, drug addiction/alcoholism, current smoking,
current heavy coffee drinking, recent surgery, major medical disorders,
or taking prescribed or over-the-counter medication of any kind. Partic-
ipants were also required to have a body mass index (BMI) between 19
and 25, be aged between 18 and 40 years old, and to be native English
speakers. These latter inclusion criteria were applied to ensure that all
participants had approximately equal physical capability to operate
the behavioral task and could understand adequately the task instruc-
tions and questionnaires. We restricted our sample to male participants
to avoid potentially confounding effects of menstruation-related hor-
monal fluctuations during the month long testing window (Kumari and
Corr, 1998).
Before each pharmacological testing session each participant under-
went an additional brief medical review in which he was asked by the
consultant psychiatrist about any changes in his health since screening,
including new use of medication, alcohol, caffeine, or tobacco in the
previous 48 h. If the physician judged that it was appropriate to proceed
with dosing, baseline vital signs (pulse and blood pressure) were recorded
and the participant ingested the drug. Following completion of each
pharmacological testing session, each participant was asked whether or
not he thought he had received an active drug or the placebo and then
underwent a posttesting medical review including vital signs measure-
ment to verify that he was fit for discharge.
Personality questionnaires
In rodents, the direction of anxiolytic drug effects upon risk assessment
behavior is determined by the animals’ state level of defensiveness: in
mildly threatened rodents (e.g., that have been exposed to the odor of a
predator) risk assessment behavior is typically reduced by anxiolytic
drugs (R. J. Blanchard et al., 1990), whereas in severely threatened ro-
dents (e.g., that are in clear sight of a nearby predator) anxiolytic drugs
typically increase risk assessment (D. C. Blanchard et al., 1990). This
bidirectional pattern of pharmacological effects has been interpreted as
reflecting the capacity of anxiolytic drugs to reduce the perceived inten-
sity of a threat (Blanchard et al., 2003). Thus, in a mildly threatened
rodent, an anxiolytic-induced reduction in perceived threat intensity is
signaled by a decrease in risk assessment behavior. In severely threatened
rodents, where more intensively defensive behavior patterns such as
freezing are prevalent, an anxiolytic-induced reduction in perceived
threat intensity is indicated by the onset of risk assessment (Blanchard
et al., 2003).
In our human translation of the MDTB, unlike the rodent version, the
participants were at no stage exposed to a deadly threat such as a predator
and additionally were made aware before participation that they were in
a tightly controlled experiment during which they could not be injured in
any way. At face value, therefore, the average state level of perceived
threat among our participants was more comparable to that of mildly
threatened rodents rather than that of severely threatened rodent sub-
jects. If correct, this analysis suggests that anxiolytic drugs should not
exert a bidirectional effect upon risk assessment behavior, but instead
Figure 1. A–C, Runway task used in the Mouse Defense Test Battery (A) and its human translation (B, C). In A, a mouse is placed
in the runway and then pursued by a hand-held anesthetized rat (rats are predators of mice). In the endless runway configuration
(without doors) the running speed of the mouse away from the rat is an index of fear. When the two doors are fitted, the frequency
of approach-withdrawal oscillations in the resulting closed alley is an index of anxiety. In B, the participant uses a force sensing
joystick to control the speed of the green dot cursor when it is trapped between two red dot threat stimuli (these replace the doors
in the mouse version). The magnitude of approach-withdrawal oscillations during this phase was used as a measure of anxiety. In
C, the average velocity of the participants’ cursor during pursuit by a single red dot threat stimulus was used as an index of fear. For
further details, see Materials and Methods.
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will reduce risk assessment, as is seen in mildly threatened rodents (R. J.
Blanchard et al., 1990). However, human trait individual differences in
perceptions of threat intensity have been likened to state individual dif-
ferences in rodent perceived threat (McNaughton and Corr, 2004),
meaning that the effect of anxiolytic drugs upon risk assessment behavior
may be modulated to some extent by individual differences in perceived
threat intensity.
To conduct a preliminary test of this possibility, we measured trait
individual differences in perceived intensity of threat in our partici-
pants using questionnaire self report. Since a validated questionnaire
measure of this construct has not yet been created, we administered
the Fear Survey Schedule (FSS) (Wolpe and Lang, 1977) on the basis
that preliminary investigations of human defensive behavior using
written threat scenarios suggest that the FSS has some capacity to
measure perceived threat intensity (Perkins and Corr, 2006; Perkins
et al., 2010).
The FSS contains two major subscales: social fear, which psycho-
metric analyses suggest is a hybrid measure of trait anxiety and fear
(Cooper et al., 2007), and tissue damage fear, which psychometric
evidence suggests is a relatively pure measure of fear (Perkins et al.,
2007). These subscales have not yet been differentiated pharmacolog-
ically and so, as a precaution, we administered both of them to our
participants as potential measures of perceived threat intensity. In
addition, because trait individual differences in perceived intensity of
threat have been likened for theoretical reasons to individual differ-
ences in trait anxiety (McNaughton and Corr, 2004), we also admin-
istered a well established questionnaire measure of this construct,
namely the Y2 (trait) scale from the Spielberger State-Trait Anxiety
Inventory (STAI) (Spielberger et al., 1983).
To assess whether or not outcomes could be
altered by individual differences in how aver-
sive the participants found the task, a brief af-
fect questionnaire [the short scale Positive
Affect and Negative Affect Schedule (Mackin-
non et al., 1999)] was administered immedi-
ately after the first completion of the behavioral
task. This questionnaire contains five negative
and five positive affect-related words (e.g.,
“distressed,” “enthusiastic,” “upset”) that the
participants rated on a five point scale to show
how they were feeling at that time. Scores on
the five negative items were totaled to provide
an indication of how aversive each participant
found the task.
Experimental paradigm
Methods. This study used a placebo-controlled,
double blind, within-subjects, repeated mea-
sures design in which pharmacological effects
on human defensive behavior were measured
in three different counterbalanced drug condi-
tions [panicolytic (10 mg of citalopram), anxi-
olytic (1 mg of lorazepam), and placebo (50 mg
of ascorbic acid)] in three separate testing ses-
sions, 7 d apart to ensure drug washout. The
drug doses were selected on the basis of previ-
ous research showing that they produce a sig-
nificant affective response with minimal side
effects (Kuepper et al., 2006). The order in
which participants received the drugs was set
by a six group randomization schedule. Each
pharmacological testing session had the same
structure (Fig. 2).
Behavioral task. We measured human defen-
sive behavior by translating the MDTB into the
form of a joystick-operated runway task
(JORT). In the MDTB, rodents are video re-
corded as they respond to different types of
threat so that their behavior may be scored af-
terward. Our human version of the MDTB
scored behavior automatically by computer allowing the experiment to
be run without need for video analysis.
Apparatus. Behavioral data were acquired using a force-sensing joy-
stick apparatus (PH-JS1, Psyal, London, UK). The participant sat on a
stool that was integral to the apparatus and operated the joystick handle
while facing a white screen measuring approx. 1.5  1.5 m. A vertically
orientated image of a runway was projected on this screen (Fig. 1 B, C) by
a purpose-written computer program (PS-JS1, Psyal, London, UK).
Testing procedure. The participant pushed the joystick handle forward
with both hands to move a cursor (a circular green dot) along the on-
screen runway ahead of a second, computer controlled pursuing cursor
(a circular red dot). In order for it to remain visible at all times, the green
dot cursor representing the participant remained motionless in the cen-
ter of the runway, with a visual impression of speed along the runway
being created by scrolling the background downward at a speed directly
proportional to the force applied to the joystick handle. A reduction in
force applied to the joystick handle slowed the green dot cursor and
allowed the red dot cursor to catch up, but the participant could not
move it backwards by pulling on the handle. The only other person in the
room during the testing session was the experimenter (A.P.) who was
seated behind the participant out of their line of sight. Computer con-
trolled instructions for each phase of the task were displayed on screen:
the experimenter did not speak during testing, unless the participant
required the experimental procedure to be clarified.
Seven days before the start of the pharmacological testing sessions, the
maximum physical strength of each participant was recorded in a re-
hearsal testing session. In this session, before attempting the avoidance
task, the participant was required to push the joystick handle five times
Pre-dosing medical review and vital signs measurement
DRUG ADMINISTRATION
ENTER WAITING ROOM
Snack of two plain biscuits and 300ml still water
(consumed 100 minutes after dosing)
EXIT WAITING ROOM
ENTER TESTING ROOM
5 trials of one way avoidance practice
10 trials of two way avoidance without threat of white noise
5 trials of one way avoidance without threat of white noise
PARTICIPANT PUTS ON HEADPHONES
1 trial pairing of white noise burst with red dot cursor
5 trials of one way avoidance with threat of white noise
10 trials of two way avoidance with threat of white noise
EXIT TESTING ROOM





































Figure 2. Program for pharmacological testing session.
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with both hands as hard as possible while seated on the joystick stool. The
minimum force required for the green dot cursor to reach escape velocity
on the runway for all subsequent pharmacological testing sessions in-
volving a participant was set at 50% of whatever maximum force that he
exerted during calibration. This procedure meant that in principle each
participant had to work equally hard to outrun the pursuing red dot
cursor relative to other participants, even if they differed in absolute
physical strength. This procedure also meant that each participant had to
work equally hard across the three pharmacological testing sessions. By
coupling runway velocity to physical effort we increased the naturalism
of our task by ensuring that avoidance of threat by our participants had
significant calorie cost, mimicking that incurred by animals in real threat
situations. The calibration level of 50% maximum strength was deter-
mined during extensive piloting to ensure that the participant must exert
non-trivial physical effort in return for avoidance of the pursuing stimuli,
without suffering severe fatigue that might confound results over con-
secutive trials.
To accommodate a wide range of individual differences in physical
strength, the joystick mechanism was designed to measure from 0 –500 N
of force applied to the handle. The handle was made out of a solid steel
rod 25 mm in diameter to resist bending or breaking during use. By
mounting the joystick on a stool, the participant’s weight served to pin
the apparatus firmly to the floor even during violent avoidance maneu-
vers. A soft rubber hand grip was fitted to the joystick handle.
Prethreat. Each pharmacological testing session began with 5 practice
trials of one-way active avoidance (Fig. 1C) that allowed the participant
to acquaint himself with the coupling of the movement of the joystick
handle with onscreen movement of the green dot cursor. The participant
then completed 10 trials of two-way active avoidance. The format for the
two-way active avoidance trials was identical to that of the one-way active
avoidance trials except for the presence of a second red dot cursor trav-
eling along the runway ahead of the green dot cursor (Fig. 1 B). Since
movement of the green dot cursor away from one red dot cursor auto-
matically moved it closer to the other (both red dot cursors moved in the
same direction), the participant was thus trapped between the two red
dot cursors in a two-way active avoidance goal conflict situation for the
duration of the trial, regardless of whether or not he slowed or accelerated
along the runway. The participant then completed 5 more trials of one-
way active avoidance.
Threat. The participant put on a pair of headphones and watched an
example trial on the screen where the green dot cursor was pursued and
then contacted by the red dot cursor upon which a 250 ms, 115 dB burst
of white noise was presented (the joystick was disabled for this phase so
that all participants received the same exposure to the white noise). The
participant then completed 5 test trials of one-way active avoidance that
were identical to the prethreat trials except that the participant received a
115 dB white noise burst whenever he failed to move the green dot cursor
fast enough to avoid the pursuing red dot. Finally participants completed
a further 10 trials of two-way active avoidance, also under threat of white
noise (contact between the green dot and either of the red dots triggered
the white noise burst). To prevent prolonged exposure to white noise, a
trial terminated automatically as soon as the participant had received a
single 250 ms, 115 dB burst of white noise. If the participant successfully
avoided the threat stimuli for 7 s the trial automatically terminated. To
enhance unpredictability, intertrial intervals were varied pseudo-
randomly between 15 and 30 s. The software controlling the joystick-
operated runway task automatically recorded the velocity (pixels/s) of
the green dot cursor every 10 ms throughout the testing session. During
intertrial intervals when no force was applied to the joystick handle the
velocity was zero.
Behavioral data analysis. Approach-withdrawal oscillation in the
closed runway configuration of the MDTB is described as part of rodent
risk assessment behavior (Griebel et al., 1995b). A link between anxiety
and approach-withdrawal oscillation in the MDTB is suggested by the
sensitivity of this behavior to anxiolytic drugs (Griebel et al., 1998; Stem-
melin et al., 2008). In line with this literature, we used the magnitude of
approach-withdrawal oscillations (measured as the SD of the average
velocity of the participants’ cursor during two-way active avoidance) as
our putative measure of risk assessment intensity in the computerized
runway task. In the MDTB escape speed is regarded as a measure of
rodent flight behavior (Griebel et al., 1995a): in the present study we
conceptualized the average velocity of the participants’ cursor during
one-way active avoidance in the endless runway configuration as our
putative measure of the intensity of flight behavior. To control for drug
effects on motor function, the behavior of each participant during one-
way and two-way active avoidance was measured before (x) and after ( y)
introduction of a threat stimulus: the pure effect of threat on behavior in
both parts of the runway task could therefore be calculated as yx for
each of the dependent variables.
The dependent variable that we labeled as risk assessment intensity
was, therefore, measured as the degree to which the introduction of
the threat of a white noise burst altered the magnitude of approach-
withdrawal oscillation during two-way active avoidance (e.g., average
oscillation in the 10 two-way active avoidance trials before exposure to
threat stimulus subtracted from average oscillation in 10 conflict trials
after exposure to threat stimulus). For the same reason, the dependent
variable that we labeled as flight intensity was measured behaviorally as
the degree to which the introduction of the threat of a white noise burst
altered the velocity of the green dot cursor along the runway during
one-way active avoidance (i.e., average velocity in the one-way active
avoidance trial immediately before exposure to threat stimulus sub-
tracted from average velocity in the one-way active avoidance trial im-
mediately after exposure to threat stimulus).
Statistical analyses. Statistical analyses were performed using the Sta-
tistical Package for the Social Sciences (SPSS). Associations between per-
sonality variables and dependent variables were assessed using Pearson’s
product-moment correlation coefficient to determine covariate eligibil-
ity. Effects of drugs and personality upon task performance were ana-
lyzed by repeated measures ANCOVA, in which Drug (citalopram,
lorazepam, placebo) formed a three level within-subjects factor. Any
personality score that met the established covariance criteria [i.e., ques-
tionnaire scores that correlated significantly with a dependent variable
(Tabachnick and Fidell, 2007)] was entered as a covariate. Simple con-
trasts were used to test for specific drug effects against placebo. The
Pearson  2 test was used to determine whether or not participants could
detect ingestion of an active drug by self report. The level for statistical
significance was set to p  0.05.
Results
Table 1 presents descriptive statistics and correlations among
questionnaire measures of personality and behavioral criteria.
The pattern of correlations between trait anxiety and fear
questionnaire scores parallels previous psychometric findings
(Cooper et al., 2007): FSS social fear more closely resembles trait
anxiety than does FSS tissue damage fear. No statistically signifi-
cant correlations emerged between ratings of task aversiveness
and psychometric variables; however, task aversiveness was sig-
nificantly positively correlated with flight intensity in the placebo
condition. This finding provides circumstantial support for the
face validity of the JORT by suggesting that participants found the
white noise burst threat stimulus to be aversive and that this
aversiveness was sufficiently potent to influence their flight
behavior in the expected direction. There were no statistically
significant correlations among the behavioral criteria, but
questionnaire scores on FSS social fear were significantly pos-
itively correlated with risk assessment intensity in the Loraz-
epam condition only, indicating that it is eligible for inclusion
as a covariate of interest in analyses of drug effects on risk
assessment intensity.
Drug effects on task performance
Analysis of covariance with repeated measures and FSS social fear
as covariate showed a significant main effect of Drug on risk
assessment intensity (F(2,56)  3.82; p  0.028) (Fig. 3A). Simple
contrasts showed that this drug effect on risk assessment was
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caused by lorazepam, as it significantly reduced risk assessment
intensity relative to placebo (F(1,28)  4.68, p  0.039) whereas cita-
lopram did not (F(1,28)  0.49; p  .826). There was no statistically
significant main effect of drug condition on flight intensity (F(2,56) 
0.51; p  0.601). There was no significant interaction between
drug condition and ratings of how aversive participants found the
task (F(2,56)  0.91; p  0.407).
Personality effects on task performance
As a preliminary contribution toward the ongoing discussion of
comparability between state emotions in animals and affective
traits in humans (McNaughton and Corr, 2004; Corr, 2008), we
also explored personality effects on task performance and found
that FSS social fear exerted a statistically significant between-
subjects main effect on risk assessment intensity (F(1,28)  4.88;
p  0.036). Participants scoring in the upper half of the sample on
FSS social fear displayed higher risk assessment intensity in all
drug conditions than participants scoring in the lower half of the
sample on FSS social fear (Fig. 3B). Among participants scoring
in the lower half of the sample on social fear, lorazepam appeared
to exert an especially strong reducing effect on risk assessment
intensity (Fig. 3B), although the FSS-by-Drug interaction nar-
rowly failed to reach statistical significance (F(2,56)  3.06; p 
0.055). There was no statistically significant main effect of FSS
social fear on flight intensity (F(1,28)  0.42; p  0.523); and nor
was there a significant interaction FSS-by-drug interaction
(F(2,56)  2.04; p  0.140).
Drug effects on nonavoidance variables
After each drug testing session the pulse
and blood pressure of all participants were
recorded. Drug condition exerted a signif-
icant main effect on pulse (F(2,56)  5.27;
p  0.008), with pulse being elevated in
the lorazepam condition relative to pla-
cebo (F(1,28)  7.18; p  0.012) but not in
the citalopram condition (F (1,28)  0.131;
p  0.720). Drug condition had no signif-
icant effect on blood pressure (F(2,56) 
0.87; p  0.426). After each drug testing
session participants were asked their opin-
ion as to whether or not they had received an
active drug or a placebo. In the citalopram
condition, 21 participants said they had re-
ceived an active drug, 7 said they had re-
ceived a placebo, and 2 said they did not
know what they had received. Statistical
testing showed that participants detected
ingestion of an active drug at levels signif-
icantly above chance ( 2 (1)  19.40, p  0.001). In the loraz-
epam condition, 21 participants said they had received an active
drug, 6 said they had received a placebo and 3 said they did not
know what they had received. Statistical testing showed that par-
ticipants successfully detected the ingestion of an active drug at
levels significantly above chance ( 2 (1)  18.60, p  0.001). In
the placebo condition, 9 participants said they had received an
active drug, 15 said they had received a placebo and 6 said they did
not know what they had received. Statistical testing showed that
participants did not detect the placebo at levels significantly
above chance ( 2 (1)  4.20, p  0.122).
Discussion
We show, first, that lorazepam significantly altered behavior dur-
ing approach to threat but not during departure from threat.
Since lorazepam is an anxiolytic drug (Gould et al., 1997), this
finding contributes to the validation of the theoretical principle
of defensive direction (McNaughton and Corr, 2004) that main-
tains anxiety is an emotion elicited by threats that require ap-
proach. The specific behavior that was altered by lorazepam
(approach-withdrawal oscillation) is one of a class of defensive
behaviors labeled as risk assessment that have been linked phar-
macologically to anxiety in rodents (Griebel et al., 1998). By dem-
onstrating an effect on approach-withdrawal oscillation of an
anxiolytic compound in humans, our results are broadly consis-
tent with earlier self-report questionnaire studies showing that
the patterning of human defensive behavior parallels that of ro-
dents (Blanchard et al., 2001; Perkins and Corr, 2006).
Figure 3. Behavioral data showing effects of drugs and personality on risk assessment intensity (error bars represent 1
SEM). A shows that risk assessment intensity was significantly reduced by lorazepam but that citalopram was not signifi-
cantly different from placebo in its effect on risk assessment intensity. B shows that risk assessment intensity was signif-
icantly increased by high levels of FSS social fear across all three drug conditions. In addition, B suggests that the effect of
lorazepam on risk assessment intensity was driven by participants scoring in the lower half of the sample on FSS social fear
(interaction: p  0.055) and participants scoring in the upper half of the sample on FSS social fear displayed a significantly
high level of resistance to the effects of lorazepam. *p  0.05.
Table 1. Descriptive statistics and inter-correlations for questionnaire measures of personality, negative affect, and behavioral criteria
Variable Mean (SD) 1 2 3 4 5 6 7 8 9 10
1. Trait anxiety 42.23 (8.98) —
2. Tissue damage fear 28.07 (13.04) 0.267 —
3. Social fear 38.77 (17.92) 0.383* 0.597** —
4. Task aversiveness 6.30 (1.73) 0.018 0.134 0.034 —
5. Flight intensity (Citalopram) 0.30 (0.10) 0.168 0.020 0.303 0.059 —
6. Flight intensity (Lorazepam) 0.18 (0.97) 0.127 0.133 0.015 0.192 0.092 —
7. Flight intensity (Placebo) 0.06 (0.56) 0.100 0.077 0.211 0.365* 0.112 0.335 —
8. Risk assessment intensity (Citalopram 0.01 (0.06) 0.110 0.188 0.109 0.197 0.145 0.305 0.005 —
9. Risk assessment intensity (Lorazepam) 0.03 (0.08) 0.051 0.240 0.483** 0.001 0.001 0.165 0.092 0.324 —
10. Risk assessment intensity (Placebo) 0.01 (0.06) 0.187 0.123 0.081 0.244 0.218 0.072 0.184 0.140 0.037 —
N  30. *p  0.05; **p  0.01.
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More contentiously, our use of unambiguous threat stimuli
could be interpreted as suggesting that the capacity of a threat
stimulus to elicit anxiety does not depend upon it being ambig-
uous, as rodent defense findings might suggest (Blanchard et al.,
2003), but instead upon whether or not it presents a goal conflict
(Gray and McNaughton, 2000). This interpretation must, how-
ever, be viewed with caution because of the constrained nature
of the defensive behaviors that were measured using the
joystick-operated version of the MDTB: For example, rodent
risk assessment behavior encompasses not only approach-
withdrawal oscillation but also movements that facilitate envi-
ronmental scanning, such as side-to-side head sweeps (Blanchard
et al., 2003). We were unable to sample these latter phenomena by
means of our joystick apparatus and so were unable to provide a
test of drug effects upon the full repertoire of rodent-like risk
assessment behaviors.
A further reason for caution when interpreting our lorazepam-
related results is provided by the finding that anxiolytic drugs have
been found to increase approach-withdrawal oscillation in the
MDTB (Griebel et al., 1998; Stemmelin et al., 2008), whereas we
found that lorazepam reduced the intensity of approach-withdrawal
oscillations in our participants. This opposite directional effect of
anxiolytic drugs on approach-withdrawal oscillation in rodent and
human data is difficult to explain with certainty. One possible an-
swer stems from the discovery that anxiolytic drugs increase risk
assessment in severely threatened rodents (D. C. Blanchard et al.,
1990) but reduce it in mildly threatened subjects (R. J. Blanchard et
al., 1990). Unlike MDTB subjects, our participants were not exposed
to a deadly predator and so their average level of perceived threat
should at face value have been more comparable to that of mildly
threatened rodents than that of severely threatened rodent subjects.
If correct, this analysis suggests that anxiolytic drugs should reduce
risk assessment in our participants, as was observed.
As an additional caveat it must be noted that behavioral re-
sponses during the two-way avoidance phase have a dual ef-
fect, decreasing distance to one threat stimulus just as they
increase distance to the other. Thus, although the threat stim-
uli used in our study were unambiguous, the responses they
elicited could be construed as containing ambiguity. This in-
terpretation suggests that considerable further research is re-
quired to clarify how the properties of a threat stimulus and
the responses to it elicit anxiety.
The absence of a significant main effect of the panicolytic drug
citalopram on approach-withdrawal oscillation could be cited as
additional support for the notion that oscillation specifically re-
lates to anxiety. However, contrary to expectations, citalopram
also failed to exert a significant main effect on flight intensity
during departure from threat. Viewed together, these two null
outcomes for citalopram limit the firmness of conclusions that
can be drawn concerning the relevance of this drug in the present
research. One explanation for an absence of citalopram effects
could be that, unlike benzodiazepine compounds, SSRI drugs
such as citalopram typically require administration for several
weeks before gaining clinical effectiveness (Wade et al., 1997). We
were unable for ethical reasons to dose our participants chroni-
cally and so this may have rendered our single citalopram dose
ineffective. Evidence on the acute effects of citalopram on rodent
defense has not yet been obtained but ethopharmacological stud-
ies using other clinically effective panicolytic drugs such as imip-
ramine and fluoxetine show that single doses of these compounds
reliably alter flight behavior [although in the opposite direction
to chronic dosing—potentiating rather than reducing flight; e.g.,
see the study by Griebel et al. (1995a)]. The use of a single citalo-
pram dose in the present study was plausible as our aim was to
show a selective effect of citalopram on flight behavior regardless
of its direction. Results indicate that a single dose is ineffective.
The absence of citalopram effects on simple avoidance behav-
ior could also be explained by the possibility that the defensive
direction model (Gray and McNaughton, 2000; McNaughton
and Corr, 2004) is incorrect with regard to fear. However, evi-
dence from nondrug studies showing that fear prone individuals
preferentially select threat responses entailing orientation away
from threat (Perkins and Corr, 2006; Perkins et al., 2009) pro-
vides relatively clear support for the fear-related aspects of the
theory and suggests that this explanation is not particularly
credible.
An alternative explanation for the absence of citalopram ef-
fects on defensive behavior may be found in the low level of threat
applied to participants in the present study: Whereas mice in the
MDTB are exposed to what is to them a deadly threat (a rat) our
participants were exposed to unpleasant but harmless white noise
bursts. The rationale for such an explanation lies in the hypoth-
esis that panic reactions and mild fear reactions are mediated by
different brain regions (periaqueductal gray and ventral prefron-
tal stream respectively; McNaughton and Corr, 2004). If it is
accepted that panic disorder is specifically characterized by recur-
rent episodes of intense fear (American Psychiatric Association,
1994), then citalopram, as an established panicolytic (Wade et al.,
1997), may act more powerfully on the brain systems responsible
for mediating intense fear than those that control mild fear. Thus
the white noise threat stimulus in the present study may not have
been sufficiently potent to prompt substantial activity in the
brain systems responsible for causing the panic reactions that are
modulated by SSRI’s such as citalopram in both clinical settings
and the MDTB.
This explanation points to a need for future research to use
functional brain imaging techniques during human defense to
distinguish the capacity of ethoexperimental tasks to activate rel-
evant brain areas, perhaps using threat stimuli such as electric
shocks that will most likely be perceived by participants as more
potent than white noise. For example, Mobbs et al. (2007) found
that as a virtual predator moved through a maze toward a cursor
controlled by the participant, brain activity (as measured by func-
tional magnetic resonance imaging) moved from the ventrome-
dial prefrontal cortex to the periaqueductal gray. The predator
delivered electric shocks to the participant if it caught the cursor,
suggesting that this mode of punishment may be sufficiently
aversive to cause a degree of panic.
Neuroimaging studies of this kind are especially relevant in
tests of the defensive direction theory as it makes clear predictions
concerning differential brain activity during simple avoidance
and approach to threat. In particular the defensive direction the-
ory maintains that the septo-hippocampal system is the seat of
anxiety but not fear (Gray and McNaughton, 2000). Thus, if the
JORT variables of flight intensity and oscillation during conflict
are related to fear and anxiety respectively then the former should
be distinguished from the latter by the addition of activity in the
septo-hippocampal system to underlying amygdala activity. It is
to be hoped that future research will test these predictions, pref-
erably alongside tests of predictions from other important theo-
ries of defensive emotion (Deakin and Graeff, 1991).
A subsidiary aim of the present research was to investigate the
notion that the effect of anxiolytic drugs upon human risk assess-
ment behavior may be modulated by individual differences in
perceived threat intensity. This possibility is suggested by the
finding that the state level of defensiveness of a rodent alters the
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effect of anxiolytic drugs on its risk assessment behavior (R. J.
Blanchard et al., 1990). Since human trait individual differences
in perceptions of threat intensity have been likened to state indi-
vidual differences in rodent defensiveness (McNaughton and
Corr, 2004), we tested this notion using self-reports of trait dif-
ferences in threat sensitivity. Results showed a trend level ten-
dency for lorazepam to reduce risk assessment intensity more
strongly in participants who scored in the lower half of the sample
on FSS social fear. Since anxiolytic drugs reduce risk assessment
in mildly threatened rodents but increase it in severely threatened
rodents (Blanchard et al., 2003) these findings imply that analo-
gies between the threat state of rodents and trait individual dif-
ferences in perceived threat intensity in humans may be valid
(McNaughton and Corr, 2004). For example, low scorers on FSS
social fear may be likened to mildly threatened rodents and high
scorers to animals that have perceived a relatively greater level of
threat.
This idea is reinforced by the additional finding that partici-
pants scoring in the upper half of the sample on FSS social fear
displayed significantly higher risk assessment intensity in all drug
conditions than participants scoring in the lower half of the sam-
ple on FSS social fear. Since the two-way avoidance phase of the
JORT was intended to cause a goal conflict, this latter finding is
especially important as social situations at face value often con-
tain goal conflict and the items in the FSS social fear scale reflect
this (e.g., public speaking; entering a room where other people
are already seated). The discovery that high scorers on this scale
showed more intense physical reactions to goal conflict than low
scorers therefore provides independent validation of the JORT as
a measure of conflict sensitivity and hence anxiety.
These findings support the notion that neuroscientific results
may be clarified by taking into account trait individual differences in
personality (Kumari et al., 2004) and concur with previous psycho-
metric findings that FSS scores may measure perceived intensity
of threat (Perkins et al., 2009) but do not explain precisely why a
questionnaire that purports to measure social fear should appear
to modulate effects of an anxiolytic drug on defensive behavior in
nonsocial situations. One explanation is provided by the recent
finding that, for humans, fear acquired through social observa-
tion engages similar neural mechanisms to nonsocial classical
fear conditioning (Olsson et al., 2007). This finding implies that
the prototypical brain systems that control mammalian reactions
to threat have, in humans, become substantially adapted for pro-
cessing social hazards, and so individual differences in the func-
tioning of such brain systems are likely to be expressed in humans
most clearly as individual differences in susceptibility to social
threat.
Despite this possibility, the necessity of using questionnaires
not originally intended as measures of defensive reactions was a
clear limitation for our study and so results support the notion
that a new generation of psychometric measures may be required
if defense-level personality traits are to be measured by means of
questionnaire in future research of the present type (Corr, 2008).
This need is illustrated especially clearly by the failure of scores on
the Spielberger Trait Anxiety Inventory (Spielberger et al., 1983)
to associate significantly with any defensive variable despite rea-
sons to believe that they should (McNaughton and Corr, 2004).
Another limitation of our study stems from our use of male
participants only. This was done to avoid confounding menstrual
cycle effects. Since rodent females typically show greater defen-
siveness than males (Litvin et al., 2008) and human females are
more prone than males to negative emotion (Farmer et al., 2003),
had we been able to use female participants we might have ob-
tained more powerful results.
In summary, we found evidence that anxiety may result from
approach to threat as predicted by the principle of defensive di-
rection. Participants’ behavior in response to clear threat that
must be approached was altered to a statistically significant de-
gree by an anxiolytic drug. This drug did not significantly affect
behavior during simple avoidance of threat. We also found a
statistically significant main effect of personality upon threat-
approach behavior that implies human defensive behavior is ul-
timately governed by a combination of situational and trait
factors.
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